Axogen, Inc. AXGN
Set alert
At close · Oct 30
After hours · Oct 30, 6:44 PM ET
- YTD
- +50.84%
- 1 year
- +117.68%
- Open
- 49.70
- Prev close
- 49.63
- Mkt cap
- 2.95B
- Vol
- 1.84M
- Avg vol
- 1.38M
- EPS
- -0.63
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 48.08
- High
- 49.88
- Forward P/E
- 69.55
- Beta
- 1.17
- Short ratio
- 3.57
- Inst. own
- 95.98%
- Dividend
- 0.00
- Ex-div date
- Jan 26, 2010
- Earnings
- Feb 23, 2027
- 50-d avg
- 42.80
- 200-d avg
- 39.48
- 1y target
- 57.73
2Y chart
Events in this range
- Oct 29, 2025Earnings: 0.12; estimate 0.09; surprise 33.33%
- Feb 24, 2026Earnings: 0.07; estimate 0.08879; surprise -21.16%
- Apr 28, 2026Earnings: 0.07; estimate 0.12; surprise -41.67%
- Jul 29, 2026Earnings: 0.12; estimate 0.1214; surprise -1.15%
- Oct 28, 2026Earnings: 0.21; estimate 0.1313; surprise 59.94%
- Oct 29, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 29, 2026Rating: Wells Fargo · Overweight → Overweight
- Oct 29, 2026Rating: Truist Securities · Buy → Buy
- Oct 29, 2026Rating: Barclays · Overweight → Overweight
- Oct 29, 2026Rating: Leerink Partners · Outperform → Outperform
- Oct 29, 2026Rating: Canaccord Genuity · Buy → Buy
Signals (80)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| SMA: Bullish | Oct 28, 2026 | 4 days ago |
| RSI: Overbought | Oct 28, 2026 | 4 days ago |
| MACD: Buy Signal | Oct 20, 2026 | 1 week ago |
| RSI: Oversold | Oct 13, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 22, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Jul 31, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 29, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 7, 2026 | 3 months ago |
| MACD: Buy Signal | Jun 11, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 10, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 9, 2026 | 4 months ago |
| MACD: Sell Signal | May 11, 2026 | 5 months ago |
| RSI: Overbought | May 5, 2026 | 6 months ago |
| RSI: Overbought | Apr 30, 2026 | 6 months ago |
| RSI: Overbought | Apr 28, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 26, 2026 | 7 months ago |
| SMA: Bullish | Mar 24, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| SMA: Bullish | Mar 16, 2026 | 7 months ago |
| MACD: Buy Signal | Mar 13, 2026 | 7 months ago |
| SMA: Bearish | Feb 24, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 24, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 23, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 9, 2026 | 8 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| RSI: Overbought | Dec 29, 2025 | 10 months ago |
| RSI: Overbought | Dec 22, 2025 | 10 months ago |
| MACD: Sell Signal | Dec 11, 2025 | 10 months ago |
| MACD: Buy Signal | Nov 20, 2025 | 11 months ago |
| RSI: Overbought | Nov 18, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 17, 2025 | 11 months ago |
| RSI: Overbought | Oct 29, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 22, 2025 | 1 year ago |
| SMA: Bullish | Oct 16, 2025 | 1 year ago |
| SMA: Bearish | Oct 13, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 25, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 19, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 2, 2025 | 1 year ago |
| SMA: Bullish | Aug 26, 2025 | 1 year ago |
| SMA: Bearish | Aug 25, 2025 | 1 year ago |
| RSI: Overbought | Aug 13, 2025 | 1 year ago |
| RSI: Overbought | Jul 23, 2025 | 1 year ago |
| SMA: Bullish | Jul 10, 2025 | 1 year ago |
| RSI: Oversold | Jun 12, 2025 | 1 year ago |
| RSI: Oversold | Jun 9, 2025 | 1 year ago |
| MACD: Buy Signal | May 30, 2025 | 1 year ago |
| RSI: Oversold | May 28, 2025 | 1 year ago |
| RSI: Oversold | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 8, 2025 | 1 year ago |
| RSI: Oversold | May 8, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 25, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 2, 2025 | 1 year ago |
| SMA: Bearish | Apr 1, 2025 | 1 year ago |
| SMA: Bullish | Mar 25, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 25, 2025 | 1 year ago |
| SMA: Bearish | Mar 18, 2025 | 1 year ago |
| SMA: Bullish | Mar 17, 2025 | 1 year ago |
| SMA: Bearish | Mar 6, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 5, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 25, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 27, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 13, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 6, 2025 | 1 year ago |
| RSI: Overbought | Dec 23, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 20, 2024 | 1 year ago |
Key statistics
- Market cap
- 2.95B
- Enterprise value
- 2.64B
- Trailing P/E
- 0.00
- Forward P/E
- 69.55
- PEG ratio
- 99.04
- Price / sales
- 11.05
- Price / book
- 5.94
- EPS (TTM)
- -0.63
- Beta
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -11.96%
- Revenue (TTM)
- 266.93M
- Revenue growth
- 26.20%
- Free cash flow
- 29.81M
- Total cash
- 348.07M
- Total debt
- 19.47M
- Return on equity
- -10.35%
- Shares outstanding
- 59.73M
- Short % of float
- 9.76%
- 50-day average
- 42.80
- 200-day average
- 39.48
Analyst view
Consensus: strong buy
- Target (low)
- 48.00
- Target (mean)
- 57.73
- Target (high)
- 65.00
- Strong buy2
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate 0.15011.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | 0.14 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.1313 | 0.21 | +0.08 | +59.94% |
| Jul 29, 2026 | Jun 30, 2026 | 0.1214 | 0.12 | 0.00 | -1.15% |
| Apr 28, 2026 | Mar 31, 2026 | 0.12 | 0.07 | -0.05 | -41.67% |
| Feb 24, 2026 | Dec 31, 2025 | 0.08879 | 0.07 | -0.02 | -21.16% |
| Oct 29, 2025 | Sep 30, 2025 | 0.09 | 0.12 | +0.03 | +33.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | Canaccord Genuity | main | Buy | Buy |
| Oct 29, 2026 | Leerink Partners | main | Outperform | Outperform |
| Oct 29, 2026 | Barclays | main | Overweight | Overweight |
| Oct 29, 2026 | Truist Securities | main | Buy | Buy |
| Oct 29, 2026 | Wells Fargo | main | Overweight | Overweight |
| Oct 29, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Axogen, Inc.
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- axogeninc.com
News
- Axogen: Taking The Friction Out Of Nerve Repair
- Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $60
- Leerink Partners Maintains Outperform on Axogen, Raises Price Target to $56
- Barclays Maintains Overweight on Axogen, Raises Price Target to $60
- Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
- Truist Securities Maintains Buy on Axogen, Raises Price Target to $60
- Wells Fargo Maintains Overweight on Axogen, Raises Price Target to $56
- Microsoft To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Thursday
- HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $56
- AxoGen Q3 Earnings Call Highlights
Your note
Sign in to keep a note on AXGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BEGAN MARC A. | General Counsel | Conversion of Exercise of derivative security | Feb 26, 2026 | 50,135 |
| DALE MICHAEL D | Chief Executive Officer | Sale | Dec 9, 2025 | 63,537 |
| DEVINNEY ERICK WAYNE | Officer | Sale | Mar 15, 2026 | 262,781 |
| HARTLEY LINDSEY MARIE | Chief Financial Officer | Sale | May 6, 2026 | 65,146 |
| KEMP JENS SCHROEDER | Officer | Sale | May 6, 2026 | 72,451 |
| LEVINE ALAN M. | Director | Conversion of Exercise of derivative security | Jun 17, 2026 | 50,893 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.40% | 4,419,208 | 218.18M | Jun 29, 2026 |
| Morgan Stanley | 4.60% | 2,747,924 | 135.67M | Jun 29, 2026 |
| First Light Asset Management, LLC | 4.60% | 2,748,361 | 135.69M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.78% | 2,257,948 | 111.47M | Jun 29, 2026 |
| Artemis Investment Management Llp | 2.98% | 1,780,992 | 87.93M | Sep 29, 2026 |
| Polar Capital Holdings PLC | 2.51% | 1,500,822 | 74.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,596,149 | 78.80M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.31% | 1,380,756 | 68.17M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.83% | 1,095,482 | 54.08M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.02% | 609,728 | 30.10M | Jun 29, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.98% | 588,200 | 29.04M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.96% | 575,481 | 28.41M | Jul 30, 2026 |